Kevin Dunleavy on Muck Rack

Kevin Dunleavy

Verified
Fairfax
As seen in: Fierce Pharma, Yahoo Sports, Miami Herald, George Washington Today, NewsBreak, Fierce Healthcare, The Top Line, Fierce Biotech, fiercebiotechresearch.com, Herald-Mail Media, Golf Pass and
Recovering sportswriter, now a reporter for @FiercePharma
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Moderna hires Novartis vet to lead commercial, upsizes role for Hoge as potential launches loom

|
By Kevin Dunleavy 
| The Top Line
As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. The company has hired Ester Banque to become its chief commercial officer and has elevated the role of president Stephen Hoge, M.D., who will now oversee each of the company’s three divisions: commercial, manufacturing and R&D.
Open in Who Shared Issue with article?

Germany backs off plan to install variable discount pricing on drugs: report

|
By Kevin Dunleavy 
| The Top Line
Following much opposition from drugmakers, Germany has scrapped its plan to install a program that would have reduced the price of branded pharmaceuticals through a variable structure, according to a report from Reuters. The country’s discount initiative was part of a proposed healthcare reform plan designed to save 16.3 billion euros ($19.1 ​billion) in 2027, with cuts in drug spending accounting for savings of 1.9 billion euros ($2.2 billion) next year.
Open in Who Shared View Duplicates (2) Issue with article?

Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield

|
By Kevin Dunleavy 
| The Top Line
After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has signed off on the expansion, albeit nearly two months later than the original target date. The accelerated nod will allow patients ages 8 to 17 who have been recently diagnosed with stage 3 Type 1 diabetes to use Tzield to delay the decline in endogenous insulin production.
Open in Who Shared View Duplicates (2) Issue with article?
See all 2,853 licensed articles (3,761 Total)

Actions

Share this page

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified